Interrogatory cell-based assays and uses thereof
AssigneeBerg Pharma LLC
InventorsVivek K. Vishnudas, Rangaprasad Sarangarajan, Niven Rajin Narain, Min Du, Tony Walshe
Life of this patent
Estimating the term…
Abstract
Described herein is a discovery Platform Technology for analyzing a biological system or process (e.g., a disease condition, such as cancer) via model building
Claims59
A method for identifying a modulator of a biological system, the method comprising:
- establishing a model for the biological system, using cells associated with the biological system, to represents a characteristic aspect of the biological system;
- obtaining a first data set from the model, wherein the first data set represents global proteomic changes in the cells associated with the biological system;
- obtaining a second data set from the model, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with the biological system, wherein said one or more functional activities or cellular responses of the cells comprises global enzymatic activity and/or an effect of the global enzyme activity on the enzyme metabolites or substrates in the cells associated with the biological system;
- generating a consensus causal relationship network among the global proteomic changes and the one or more functional activities or cellular responses based solely on the first and second data sets using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first and second data sets;
- and
- identifying, from the consensus causal relationship network, a causal relationship unique in the biological system, wherein at least one enzyme associated with the unique causal relationship is identified as a modulator of the biological system.
(canceled)
16-17. (canceled)
21-24. (canceled)
26-33. (canceled)
36-42. (canceled)
44-48. (canceled)
A method for identifying a modulator of a biological system, the method comprising:
- establishing a model for the biological system, using cells associated with the biological system, to represents a characteristic aspect of the biological system;
- obtaining a first data set from the model, wherein the first data set represents global proteomic changes in the cells and one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data characterizing the cells associated with the biological system;
- obtaining a second data set from the model, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with the biological system, wherein said one or more functional activities or cellular responses of the cells comprises global kinase activity and/or an effect of the global kinase activity on the kinase metabolites or substrates in the cells associated with the biological system;
- generating a consensus causal relationship network among the global proteomic changes, the one or more of lipidomic, metabolomic, transcriptomic, genomic, and SNP data, and the one or more functional activities or cellular responses based solely on the first and second data sets using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first and second data sets;
- and
- identifying, from the consensus causal relationship network, a causal relationship unique in the biological system, wherein at least one kinase associated with the unique causal relationship is identified as a modulator of the biological system.
53-55. (canceled)
A method of diagnosing or prognosing a disease in a mammalian subject, the method comprising:
- determining an expression or activity level, in a biological sample obtained from the subject, of any one or more proteins of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21;
- and
- comparing the level in the subject with the level of expression or activity of the one or more proteins in a control sample,
- wherein a difference between the level in the subject and the level of expression or activity of the one or more proteins in the control sample is an indication that the subject is afflicted with a disease, or predisposed to developing a disease, or responding favorably to a therapy for a disease, thereby diagnosing or prognosing the disease in the mammalian subject.
(canceled)
A method of identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject, the method comprising:
- contacting a cell with a test compound;
- determining the level of expression, in the biological sample, of any one or more proteins of TCOF1, TOP2A, CAMK2A, CDK1, CLTCL1, EIF4G1, ENO1, FBL, GSK3B, HDLBP, HIST1H2BA, HMGB2, HNRNPK, HNRPDL, HSPA9, MAP2K2, LDHA, MAP4, MAPK1, MARCKS, NME1, NME2, PGK1, PGK2, RAB7A, RPL17, RPL28, RPS5, RPS6, SLTM, TMED4, TNRCBA, TUBB, and UBE21;
- comparing the level of expression of the one or more proteins in the cell with a control cell not contacted by the test compound;
- and
- selecting the test compound that modulates the level of expression of the one or more proteins in the cell,
- thereby identifying a therapeutic compound for treating, alleviating a symptom of, inhibiting progression of, or preventing a disease in a mammalian subject.
59-60. (canceled)
A method for identifying a modulator of angiogenesis, said method comprising:
- (1) establishing a model for angiogenesis, using cells associated with angiogenesis, to represents a characteristic aspect of angiogenesis;
- (2) obtaining a first data set from the model for angiogenesis, wherein the first data set represents one or more of genomic data, lipidomic data, proteomic data, metabolomic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis;
- (3) obtaining a second data set from the model for angiogenesis, wherein the second data set represents one or more functional activities or cellular responses of the cells associated with angiogenesis;
- (4) generating a consensus causal relationship network among the one or more of genomic data, lipidomic data, proteomic data, metabolic data, transcriptomic data, and single nucleotide polymorphism (SNP) data characterizing the cells associated with angiogenesis, and the one or more functional activities or cellular responses of the cells associated with angiogenesis based solely on the first data set and the second data set using a programmed computing device, wherein the generation of the consensus causal relationship network is not based on any known biological relationships other than the first data set and the second data set;
- (5) identifying, from the consensus causal relationship network, a causal relationship unique in angiogenesis, wherein a gene, lipid, protein, metabolite, transcript, or SNP associated with the unique causal relationship is identified as a modulator of angiogenesis.
(canceled)
66-68. (canceled)
70-72. (canceled)
75-82. (canceled)
84-85. (canceled)
(canceled)
93-94. (canceled)
96-111. (canceled)
Dependencies are inferred from the claim text.